Search

everythinglearnresearchcommunity

for

Search:↓

Special cells can help regrow hair in alopecia areata.

Targeting CXCL10 may help treat alopecia areata.

Targeting specific T cells may help treat alopecia areata.

T cells and inflammation are crucial in atherosclerosis, with anti-inflammatory treatments showing promise.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.

Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.

Antroquinonol may help prevent skin depigmentation by suppressing certain immune cells.

People with severe hair loss have higher levels of a protein called interleukin 17 in their blood.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Tridax procumbens plant parts boost immune response in mice.

Higher IL-17A levels indicate more severe alopecia areata.

Clascoterone may be an effective topical treatment for hair loss.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

JAK inhibitors are effective treatments for alopecia areata.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Higher Interleukin 17A levels may indicate more severe alopecia areata.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.

Belatacept may be a promising treatment for alopecia areata.

TH antibodies in vitiligo and AA patients recognize the same protein parts.

Enhancing immune response can improve cancer treatment effectiveness.